Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

UPDATE REGARDING THE ASARINA PHARMA SHARE

The Asarina Pharma shares were delisted from NASDAQ First North in October 2024 after an Extraordinary General Meeting decided to liquidate the company. After the delisting, it is no longer possible to trade the Asarina Pharma shares.

In February 2025, Asarina Pharma sold all its IP assets to Relmada Therapeutics, a neurology company in the US (see press release on this website).

After the sale of the IP assets to Relmada, the company is winding its remaining operations and paying its creditors. If there is cash remaining at the end of the liquidation, it will be distributed to the shareholders.

Asarina Pharma sells Sepranolone assets to Relmada Therapeutics 2025-02-07 08:30

Stockholm, 7 February 2025. Asarina Pharma AB (“Asarina” or “the Company”) today announces that it has signed an Asset Purchase...

Asarina Pharma AB (publ) shares to be delisted and the last day of trading is 1 October 2024 2024-09-16 20:00 Regulatory

Asarina Pharma AB (publ) ("Asarina" or the "Company") announced on 13 September 2024 that the Company has applied for the delisting...

Asarina Pharma applies for the delisting of the company's shares 2024-09-13 11:00 Regulatory

Stockholm, September 13, 2024. An extraordinary general meeting of Asarina Pharma AB (publ) ("Asarina" or the "Company") decided on...

Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma 2024-08-21 11:30 Regulatory

Asarina Pharma AB (publ) held on 21 August 2024 an extraordinary general meeting, and first control meeting, at which the shareholders resolved that the...

NOTICE OF EXTRAORDINARY GENERAL MEETING AND FIRST CONTROL MEETING IN ASARINA PHARMA AB (PUBL) 2024-07-22 08:00 Regulatory

The shareholders of Asarina Pharma AB (publ), reg. no. 556698-0750, (the “Company”) are hereby given notice to attend the extraordinary general...

ASARINA PHARMA ANNOUNCES OUTCOME OF PARTNERING PROCESS, CONTROL BALANCE SHEET AND PROPOSAL TO LIQUIDATE 2024-07-18 17:45 Regulatory

Asarina Pharma AB (publ) ("Asarina Pharma” or the ”Company”) today announces that the Company is discontinuing its efforts to find...

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ) 2024-06-27 11:33 Regulatory

The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (the “Company”) on...

ASARINA PHARMA AB (PUBL) RELEASES ANNUAL REPORT 2023 2024-06-04 22:54 Regulatory Annual

(Stockholm, 4 June 2024) Asarina Pharma (“the Company”) today announces the release of its 2023 Annual Report. Status and OutlookSince completing...

Asarina Pharma AB announces new date for the release of Annual Report for 2023 2024-05-28 22:00 Regulatory

Asarina Pharma AB (publ) (”the Company”) announces today that the Board has decided to postpone the release of the Annual Report for 2023 to...

Asarina Pharma AB announces new date for the release of Annual Report for 2023 2024-05-21 11:50 Regulatory

Asarina Pharma AB (publ) (”the Company”) announces today that the Board has decided to postpone the release of the Annual Report for 2023 to...